FDA expands Daxxify label to include cervical dystonia treatment

Daxxify (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment of cervical dystonia in adults. The recommended dose for cervical dystonia is 125 to 250 Units given intramuscularly as a divided dose among affected muscles.